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Objective: Studies on the effects of ischemic preconditioning in the human heart
have yielded conflicting results and therefore remain controversial. This study
investigated whether ischemic preconditioning was able to protect against myocar-
dial tissue damage in patients undergoing coronary artery surgery with cardiopul-
monary bypass and on the beating heart.
Methods: A total of 120 patients were studied and divided into 3 groups: group I:
cardiopulmonary bypass with intermittent crossclamp fibrillation; group II: cardiopul-
monary bypass with cardioplegic arrest using cold blood cardioplegia; group III: surgery
on the beating heart. In each group (n  40), patients were randomly subdivided (n 
20/subgroup) into control and preconditioning groups (1 cycle of 5 minutes of isch-
emia/5 minutes reperfusion before intervention). Ischemic preconditioning was induced
by clamping the ascending aorta in groups I and II or by clamping the coronary artery
in group III. Serial venous blood levels of troponin T were analyzed before surgery and
at 1, 4, 8, 24, and 48 hours after termination of ischemia. In addition, in vitro studies
using right atrial specimens obtained before the institution of cardiopulmonary bypass,
and then again 10 minutes after initiation of bypass, were performed. The specimens
were equilibrated for 30 minutes before being allocated to 1 of the following 2 groups
(n 6 per group): (1) ischemia alone (90 minutes of ischemia followed by 120 minutes
of reoxygenation) or (2) preconditioning with 5 minutes of ischemia and 5 minutes of
reoxygenation before the long ischemic insult. Creatine kinase leakage (U/g wet weight)
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction (mmol/l per
gram wet weight), an index of cell viability, were assessed at the end of the experiment.
Results: There were no perioperative myocardial infarctions or deaths in any of the
groups studied. The total release of troponin T was similar in groups I and II (patients
undergoing surgery with cardiopulmonary bypass) and in the release profile; they were
unaffected by ischemic preconditioning. In contrast, the total troponin T release for the
first 48 hours was significantly reduced by ischemic preconditioning in group III
(patients undergoing surgery without cardiopulmonary bypass) from 3.1 0.1 to 2.1
0.2 ng · h · mL. Furthermore, the release profile that peaked at 8 hours in the control
group shifted to the left at 1 hour. In the in vitro studies, the atrial muscles obtained
before cardiopulmonary bypass were protected by ischemic preconditioning (crea-
tine kinase  2.6  0.2 and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide reduction  152  24 vs creatine kinase  5.4  0.6 and 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reduction  87  16 in
controls; P  .05); however, the muscles obtained 10 minutes after initiation of
cardiopulmonary bypass were already protected (creatine kinase  0.8  0.1 and
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reduction  316 
38), and ischemic preconditioning did not result in further improvements.
Conclusions: Ischemic preconditioning is protective in patients undergoing coronary
artery surgery on the beating heart without the use of cardiopulmonary bypass, but it
offers no additional benefit when associated with bypass regardless of the mode of cardio-
protection used, because cardiopulmonary bypass per se induces preconditioning.
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Myocardial injury, manifested as tran-sient cardiac contractile dysfunction(“stunning”) and myocardial necro-sis, is the most frequent complicationduring heart surgery.1 Ischemic pre-conditioning (IP), a powerful form of
endogenous protection against stunning and infarction, has
been demonstrated in a variety of animal species2-4 and in
vitro experiments involving isolated human cardiomyo-
cytes5 and human atrial trabeculae.6,7 For logistic and eth-
ical reasons, no clinical study can meet the strict conditions
of experimental studies on preconditioning with infarct size
as the end point. As a result, human in vivo studies have
produced conflicting results, and the role of IP in humans
remains controversial.
Yellon and coworkers8 were the first to report that IP
protects the human heart in the setting of cardiac surgery by
use of the conservation of myocardial adenosine triphos-
phate (ATP) content as the major end point. However,
Perrault and colleagues9 reported that in the presence of
cardioplegic arrest, there was no difference in the release of
biochemical markers (CK-MB) between the preconditioned
and control groups. The lack of additional protection con-
ferred by IP was further confirmed by the absence of dif-
ference in the postarrest myocardial levels of ribonucleic
messengers coding for cardioprotective heat shock proteins
between the 2 groups. Similar negative results were reported
by Kaukoranta,10 Di Salvo,11 and their colleagues, who
went on to report that in the presence of hypothermia, no
beneficial effect of preconditioning was observed in similar
patients undergoing surgery with intermittent fibrillation
techniques.
The apparent discrepancy between results obtained with
noncardioplegic and cardioplegic techniques could be rec-
onciled if one takes into account a possible hypothesis:
Preconditioning and its salutary effects are only observed in
situations of unprotected ischemia. With this in mind, this
study (1) investigates whether IP with 5 minutes of ischemia
followed by 5 minutes of reperfusion is protective in pa-
tients undergoing coronary artery bypass graft surgery with
cardiopulmonary bypass (CPB) using cardioplegia and ven-
tricular fibrillation techniques and in patients undergoing
coronary artery bypass graft surgery on the beating heart
without CPB and (2) elucidates the underlying cause of any
protection.
Methods
In Vivo Studies
Patient selection and study groups. A total of 120 patients
with stable angina who underwent operations performed by a
single surgeon (M.G.) were entered in the study. They were
divided into 2 groups: those undergoing surgery with CPB (ie,
on-pump) and exhibiting 3-vessel coronary disease (n  80) and
those undergoing surgery on the beating heart without CPB (ie,
off-pump) and with single- or double-vessel coronary artery dis-
ease (n  40). Patients in the CPB group were randomized by use
of a computer-generated random table to undergo surgery (1) with
CPB and intermittent crossclamp fibrillation  IP (n  20 in each
subgroup) or (2) with cold blood cardioplegia IP (n 20 in each
subgroup). Similarly, patients undergoing surgery on the beating
heart without CPB were randomized to receive or not receive IP (n
 20 in each subgroup). IP was induced by clamping the ascend-
ing aorta for 5 minutes at 37°C when CPB was used or by
occluding the coronary artery to be grafted for the same period and
then reperfusing for 5 minutes before the bypass graft was per-
formed. We have demonstrated that this IP protocol is the most
protective in the human myocardium.7 Patients with low ejection
fractions (30%), unstable angina, recent myocardial infarctions
(1 month), additional cardiac diseases, severe noncardiac dis-
eases, or diabetes, and who were receiving medication that in-
cluded ATP-dependent potassium channel (KATP) openers were
excluded. The study was approved by the local ethics committee,
and all patients gave written informed consent to participate in the
study. Preoperative characteristics of the patients are highlighted in
Table 1.
Operative procedure. Anesthetic technique was standardized
for all patients. Anesthesia was induced by fentanyl and main-
tained with enflurane in all patients. All operations were performed
through a median sternotomy and with full heparinization (3
mg/kg intravenously). CPB was conducted with nonpulsatile per-
fusion flow (2.2-2.4 L · min1 · m2) with ascending aortic
cannulation and 2-staged venous cannulation and moderate sys-
temic hypothermia (32°C). When cardiac arrest was achieved with
cold blood (6-10°C) cardioplegia, 1000 mL of the solution
(composition in mmol/L: 16 MgCl2 6H20; 2 CaCl2; 20 KCl; 147
NaCl; 1.0 procaine HCl, pH 7.40) was mixed with blood from
the pump in a ratio of 1:1 and injected into the aortic root
immediately after aortic crossclamping to obtain a myocardial
temperature of 12°C to 15°C. An additional dose of 500 mL of
cardioplegic solution was injected after 30 minutes of ischemia.
In the group in which intermittent aortic crossclamp fibrillation
was used, reperfusion was performed for 3 minutes between
each period. One single distal coronary artery anastomosis was
performed during each ischemic period. Proximal anastomosis
was completed on the beating heart with an aortic partial
occlusion clamp in all groups.
In the off-pump group, coronary bypass grafting was performed
on the beating heart using the Octopus myocardial stabilization
device (Medtronic Inc., Minneapolis, Minn). The suction cups
were placed on the epicardial surface on either side of the artery to
be grafted, with a suction pressure of no more than 600 mm Hg.
Small coronary clamps were applied to the proximal and distal
sites of the anastomosis with just enough pressure to occlude
coronary flow and therefore allow grafting in a bloodless field. The
clamps were released when the anastomosis was complete. The
proximal anastomosis was performed with a partial occlusion
aortic clamp.
IP was applied before the first dose of cardioplegic solution or
immediately before the aortic cross-application or the coronary
artery occlusion. The use of a Khuri Tissue pH Analyzer (Vascular
Tech, Boston, Mass) showed that the pH of the myocardium
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decreased from greater than 7.3 to less than 7.0 at the end of the
5-minute IP insult in all cases.
Assessment of myocardial injury. Serial venous blood sam-
ples were collected before induction of anesthesia and at 1, 4, 8,
24, and 48 hours after termination of ischemia in every patient for
the assessment of troponin T (TnT). This was measured by use of
the commercially available enzyme-linked immunoabsorbent as-
say kit TnT (Boehringer Mannheim, Mannheim, Germany). The
lower detection limit of the assay was 0.05 ng/mL, and concen-
trations greater than the discriminator value of 0.1 ng/mL were
considered elevated.
Hemodynamic measurements. Heart rate, mean pulmonary
artery pressure, pulmonary capillary wedge pressure, and cardiac
output were monitored with a pulmonary artery flotation catheter.
Derived cardiovascular variables, including cardiac index and sys-
temic and pulmonary vascular resistance, were calculated by stan-
dard formulas. Hemodynamic data were collected at 4 time points:
baseline (just after induction of anesthesia) and 1, 3, and 24 hours
after the termination of ischemia. Changes in derived variables
were calculated and compared.
In Vitro Studies
Specimens of human right atrium appendage were obtained from
patients undergoing elective coronary artery surgery with CPB.
Samples were obtained before the institution of CPB and again
10 minutes after the initiation of CPB. Two 6-0 Prolene (Ethi-
con Inc, Somerville, NJ) encircling sutures were placed in the
epicardial layer of the appendage once the pericardium was
opened. During the entire period of harvesting, the atrium was
exposed to the systemic circulation. The prebypass sample was
then harvested, and a 2-stage venous cannula was inserted in the
free wall of the right atrium 3 cm away from the appendage.
CPB was then instituted, and after 10 minutes, a further sample
of appendage was harvested. In each case, specimens were
quickly immersed in cold (4°C) Krebs-Henseleit-HEPES me-
dium, which comprised (in micromoles per liter) NaCl, 118;
KCl, 4.8;, NaHCO3, 27.2; KH2PO4, 1; MgCl2, 1.2; CaCl2, 1.25;
glucose, 10; and HEPES, 20. The medium was pre-bubbled with
95% O2/5% CO2 to attain a PO2 of 25 to 30 kPa and pH 7.4. The
atrial appendage was immediately sliced freehand with Swann-
Morton skin graft blades (Swann-Morton Ltd, Sheffield, United
Kingdom) to a thickness of 0.3 to 0.5 mm and a weight of 5 to
10 mg each, as previously described.12 In brief, the tissue was
placed with its epicardial surface face down on filter paper fixed
to a rectangular glass base (5  25 cm). A ground glass slide
(2.5  7.5 cm) was then pressed against the tissue, and the
blade was drawn between the slide and tissue. The slicing
apparatus and the tissue were kept wet at all times with medium
that was stored on ice (4°C-10°C). The specimens were equil-
ibrated for 30 minutes before being randomly allocated to 1 of the
following 2 groups (n  6 each from different patients/group): (1)
ischemia alone (90 minutes of ischemia followed by 120 minutes
of reperfusion) or (2) IP with 5 minutes of ischemia and 5 minutes
of reperfusion before 90 minutes of ischemia followed by 120
minutes of reperfusion. For the induction of simulated ischemia,
the medium was bubbled with 95% N2/5%CO2 (pH 6.80-7.00),
and D-glucose was removed and substituted with D-2-deoxyglu-
cose (10 mmol/L). The slices were maintained at 37°C during
the entire ischemic period. Monitoring of PO2 with an oxygen
detector electrode (Oxylite; Oxford, United Kingdom) revealed
that the PO2 in the medium was 0 kPa. Tissue pH was not
measured in the atrial sections. At the end of the ischemic
period, the nonoxygenated medium was removed, and the slices
were rinsed with oxygenated medium (O2/CO2, 19:1) and in-
cubated in 5 mL of oxygenated medium containing 10 mmol/L
glucose at 37°C for a further 120 minutes.
Tissue injury was determined by measuring the leakage of
creatine kinase (CK) into the incubation medium during the
120-minute reperfusion period. This was assayed by a kinetic
ultraviolet method based on the formation of nicotinamide
adenine dinucleotide (Sigma Catalog No. 1340-K), and the
results were expressed as U/g wet weight. Tissue viability was
assessed by the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide (MTT) to blue formazan product
at the end of the experimental time. In this assay, the yellow
MTT is reduced to a blue formazan product by the mitochondria
of viable tissue.
The tissue was loaded into a Falcon conical tube (15 mL)
(Becton Dickinson Labware, Franklin Lakes, NJ) to which 2 mL of
phosphate buffer solution (0.05 mol/L) containing MTT (1.25
mg/mL, 3 mmol/L at final concentration) was added and then
incubated for 30 minutes at 37°C. After this, the tissue was
homogenized in 2 mL of dimethyl sulfoxide (Homogenizer Ultra-
Turrax T25, dispersing tool G8, IKA-Labortechnic, Staufen, Ger-
TABLE 1. Patient characteristics and perioperative data
Variable
With CPB Without CPB
Intermittent crossclamp Cold blood cardioplegia
Control PCControl PC Control PC
Number 20 20 20 20 20 20
Age (yr  SD) 66.9 5.4 63.7 4.2 61.4 9.2 63.8 5.9 61.2 2.7 59.2 6.4
LVEF (%  SD) 60.2 5.5 61.8 4.1 62.1 5.7 63.7 4.9 59.7 9.2 65.1 6.4
No. of grafts/patient 3.8 1.5 3.6 0.8 3.7 1.2 4.1 0.7 1.15 0.6 1.2 0.5
Ischemic time/graft
(min  SD)
16.1 2.5 15.4 3.1 17.2 4.9 14.7 5.7 17.8 7.9 16.9 4.7
CPB time (min  SD) 66.4 12.7 70.4 11.4 71.4 13.4 69.8 6.7
PC, Preconditioning; LVEF, left ventricular ejection fraction (expressed as a percentage  standard deviation); CPB, cardiopulmonary bypass.
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many) at 9500 rpm for 1 minute. The homogenate was then
centrifuged at 1000g for 10 minutes, and 0.2 mL of the supernatant
was dispensed into a 98-well flat-bottom microtiter plate (Nunc
Brand Products, Denmark). After this, the absorbance was mea-
sured on a plate reader (Benchmark; Bio-Rad Laboratories, Her-
cules, Calif) at 550 nm, and the results were expressed as micro-
moles per liter per milligram wet weight.
Statistical Analysis
Statistical analyses were performed using the SPSS 9.0 statistical
package program (SPSS Inc, Chicago, Ill) to investigate the effi-
cacy of IP in the various groups of patients. Patients undergoing
surgery without CPB demonstrated less severe coronary artery
disease than those undergoing surgery with CPB (Table 2), and
because of this, comparison between patients with and without
CPB was not performed. A nonparametric test (Mann-Whitney U)
was performed for non-Gaussian distribution of data. An unpaired
Student t test was used for continuous data (2-tailed), and the 2
test for categoric data was used to compare variables between the
groups. Repeated-measures analysis of variance was used to test
the repeated observation variables postoperatively. The area under
the curve was calculated by the method of Matthews and col-
leagues.13 Data were presented as mean  SD.
Results
In Vivo Studies
There were no operative deaths (first 30 postoperative days)
or perioperative myocardial infarctions in any of the study
groups. Table 1 shows that the patient characteristics and
perioperative data were similar within each study group, and
that there was no difference between patients who were
treated with or without IP.
Plasma Troponin T
Figure 1 (A and B) shows that the profile of TnT release
in plasma was identical in patients undergoing coronary
surgery with CPB whether they were protected with
intermittent fibrillation or cold blood cardioplegia. Thus,
there was a significant increase in plasma TnT by 1 hour
after termination of ischemia that peaked at 4 hours, with
mean values still remaining elevated at 48 hours.
Notably, preconditioning did not alter this profile in both
groups, indicating that preconditioning conveys no
benefit to patients undergoing coronary surgery with
CPB.
TABLE 2. Patients’ hemodynamic data
Groups Variable HR
Mean MAP
(mm Hg)
CVP
(mm Hg)
Mean PAP
(mm Hg)
PCWP
(mm Hg)
CI
(L · m2 · min1)
PVRI
(dyn · s · cm5 · m2)
SVRI
(dyn · s · cm5 · m2)
Preoperative
Crossclamp PC 68.4 2.7 71.8 5.7 10.3 0.8 20.4 3.1 5.8 2.1 2.8 0.2 195 11 1568 102
PC 75.8 2.3 69.4 3.5 9.8 2.1 19.4 5.2 6.4 3.9 2.4 0.4 182 20 1602 53
BCP PC 59.4 9.4 65.7 6.9 7.8 5.7 22.6 6.4 5.1 2.6 2.9 0.4 201 13 1497 33
PC 65.1 6.8 70.2 2.1 9.1 2.4 25.1 9.3 7.4 1.3 3.05 0.19 215 25 1629 98
Off-pump PC 52.4 2.9 59.8 8.7 5.6 2.2 15.9 11.4 9.3 1.5 2.52 0.54 156 12 1307 109
PC 49.5 9.7 61.4 11.2 6.7 4.1 21.7 4.8 5.7 2.8 2.74 0.29 168 25 1567 63
1 h after termination of ischemia
X-clamp PC 101.3 1.9 65.4 4.7 9.4 1.2 18.1 2.7 10.4 1.3 2.56 0.31 217 20 2001 52
PC 95.6 2.4 59.4 7.2 11.2 2.7 22.4 5.1 8.5 2.1 2.06 0.28 271 16 1959 257
BCP PC 99.8 10.471.2 5.9 8.6 3.5 16.4 6.9 11.3 1.4 2.76 0.22 301 27 2106 554
PC 92.7 4.9 64.8 6.8 10.2 2.9 21.9 2.4 9.4 3.8 2.98 0.15 357 12 1903 261
Off-pump PC 105.5 6.5 75.4 8.7 11.6 3.9 24.7 9.4 12.1 2.6 2.02 0.26 298 21 1506 23
PC 112.2 9.2 77.6 6.2 13.5 5.7 19.7 3.1 10.5 1.1 2.43 0.18 312 12 1709 143
3 h after termination of ischemia
Crossclamp PC 92.4 11.567.5 5.9 7.7 3.2 20.9 5.2 11.9 6.4 2.52 0.38 256 17 1954 106
PC 84.2 12.771.8 11.8 9.2 2.7 19.8 3.4 9.7 2.9 2.21 0.27 291 67 2304 328
BCP PC 95.3 15.167.8 11.9 9.8 2.4 23.7 6.8 10.2 1.9 2.64 0.12 333 29 1796 447
PC 105.3 24.977.4 4.9 10.7 3.1 22.7 3.6 11.6 2.7 2.57 0.25 401 46 1667 169
Off-pump PC 79.5 12.971.5 12.7 9.4 2.5 21.9 2.7 8.4 2.5 2.11 0.15 412 29 1509 225
PC 86.7 14.775.1 8.3 7.9 4.2 26.4 5.9 9.6 1.6 2.92 0.26 368 36 1882 203
24 h after termination of ischemia
Crossclamp PC 61.5 6.4 62.7 2.9 6.4 2.9 19.2 2.7 5.8 2.3 2.96 0.26 208 22 1804 234
PC 72.9 5.8 58.4 9.1 7.6 6.1 16.7 4.9 10.4 3.7 2.35 0.36 214 50 2004 102
BCP PC 77.9 9.6 61.9 4.6 5.4 3.8 21.6 5.8 9.2 1.5 2.55 0.46 289 16 1620 98
PC 75.4 11.371.3 6.1 7.8 1.6 24.9 1.1 4.6 2.8 3.19 0.53 295 26 1492 207
Off-pump PC 91.6 8.7 88.1 5.3 4.4 0.8 19.6 4.6 7.8 3.8 2.46 0.34 312 28 1623 115
PC 84.3 10.490.1 2.8 6.8 1.7 23.3 3.3 10.2 1.4 2.89 0.41 256 33 2006 204
BCP, Blood cardioplegia; CI, cardiac index; CVP, central venous pressure; HR, heart rate; MAP, mean arterial pressure; PAP, pulmonary artery pressure;
PCWP, pulmonary capillary wedge pressure; PVRI, pulmonary vascular resistance index; SVRI, systemic vascular resistance index. Data are expressed as
mean  standard deviation.
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In contrast, as shown in Figure 1C, the profiles of plasma
TnT were different in patients with or without precondition-
ing and off-pump surgery. Peak release occurred by 8 hours
after termination of ischemia in the control group. Peak
release occurred by 1 hour in the preconditioned group with
a sharp decrease during the next 3 hours and with signifi-
cantly lower mean plasma TnT values than in the control
group. The significance of the accelerated rate of enzyme
leakage in the preconditioning group is not entirely clear,
but it could be the result of changes within the biophysical
properties induced by IP (thus allowing a greater transient
leakage of intracellular enzymes) or of greater cumulative
ischemic time in the preconditioned group compared with
the control group. TnT levels were similar in both groups
only by the end of 48 hours.
Figure 2 shows that the cumulative plasma release of
TnT (ie, area under the curve) was similar in the patients
undergoing surgery with CPB with no significant effect of
preconditioning. It also shows that TnT release was lower in
patients undergoing surgery without CPB, and that precon-
ditioning in this group significantly reduced the total TnT
release by 33% when compared with the control group (2.1
 0.1 vs 3.1  2 ng · h1 · mL1 P  .05).
Hemodynamic Data
Table 2 shows that the mean systemic arterial pressures,
heart rate, mean pulmonary artery pressures, systemic and
pulmonary vascular resistance, and cardiac indices fluctu-
ated within normal ranges after the operation in both the
control and preconditioned groups and in the groups with
and without CPB.
In Vitro Studies
Figure 3 (A and B) shows the results of the CK leakage and
MTT reduction of the atrial slices obtained before bypass
and 10 minutes after initiation of CPB. The results demon-
strate that the increase in CK leakage and the decrease in
MTT reduction caused by ischemia and reoxygenation in
the atrial muscles obtained before the institution of bypass
were significantly improved in the slices obtained 10 min-
Figure 1A. Time course of release of plasma cardiac troponin T (TnT) concentrations in patients undergoing
coronary artery bypass grafting with CPB and aortic crossclamping. In each group, patients were randomly
subdivided into control and preconditioning groups (n  20/group). Data are expressed as mean  SD (*P < .05
vs control group).
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utes after the initiation of bypass, and that this level of
protection was identical to that of preconditioning. Thus,
muscles that were obtained 10 minutes after the initiation of
bypass were already preconditioned, and the application of
IP did not result in additional benefit compared with IP
alone.
Discussion
The present study shows that the human heart is precondi-
tioned by the institution of CPB, and that the use of IP in
combination with other protective interventions such as
cardioplegia does not result in additional protection. It also
clearly demonstrates that the human heart can be protected
Figure 1. Cont’d. Time course of release of plasma cardiac TnT concentrations in patients undergoing coronary
artery bypass grafting with CPB and cold blood cardioplegia (B) and on the beating heart without CPB (C). In each
group, patients were randomly subdivided into control and preconditioning groups (n  20/group). Data are
expressed as mean  SD (*P < .05 vs control group).
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by IP when patients undergo surgery without the use of
CPB. These findings have obvious important clinical impli-
cations, and they warrant further discussion.
Preconditioning of the Human Heart
Experimental findings on IP cannot be directly extrapolated
to humans because the mechanisms may be different from
other animal species. For both logistic and ethical reasons,
no clinical study can meet the strict conditions of experi-
mental studies on preconditioning in which infarct size is
the primary end point; instead, surrogate end points have to
be used. As a result, the demonstration of this phenomenon
in the setting of cardiac surgery has been controversial.
Yellon and colleagues8 were the first to examine the effect
of two 3-minute ischemic episodes, in which each was
followed by 2-minute reperfusion on myocardial high-en-
ergy phosphate content, in patients undergoing coronary
artery bypass graft surgery with CPB. They claimed that the
human myocardium showed the typical biochemical fea-
tures of preconditioning observed by Murry and col-
leagues14 in their classic canine model of IP and thus could
be preconditioned. There have been recent studies15,16 also
highlighting the potential benefits of preconditioning in the
cardiac surgery setting. However, Perrault and associates9
failed to show a beneficial effect of IP when this was
induced with 3-minute aortic crossclamping followed by
2-minute reperfusion before the administration of warm
blood cardioplegia. Similar findings have been reported by
other investigators10,17 questioning the ability of precondi-
tioning to protect the human heart. The dispute on whether
preconditioning confers cardioprotection during cardiac sur-
gery is further fueled by a more recent study by Alkhulafi
and colleagues.18 By use of a protocol identical to the one
used in their first study,8 Alkhulafi and coworkers showed a
reduction of TnT release at 72 hours in patients exposed to
preconditioning, but not at 24 or 48 hours. Notably, the
same authors reported an absence of protection in myocar-
dial high-energy phosphates (in contrast with their first
study). These opposing results are puzzling and contrast
with the overwhelming evidence that preconditioning is
cardioprotective during coronary angioplasty19 and in vitro
experimental conditions using atrial trabeculae6,7 or isolated
myocytes.20 Our finding that CPB can act as a precondi-
tioning stimulus in humans is supported by another study in
sheep21 and sheds light on the previously mentioned con-
troversy.
During cardiac surgery, there may be preoperative and
intraoperative factors such as opioid agonists22 and anes-
thetic agents23 that may mimic the protection of precondi-
tioning. These include the use of opioid agonists, aprotinin,
and, notably, CPB. It has been reported that inhalational
anesthetics can induce cardioprotection, and that this effect
differs with the agent used.24,25 In the present study, enflu-
rane was used. Although enflurane is less effective than
other inhalational anesthetics,24 and IP was shown to be
cardioprotective in the off-pump group, it may not be pos-
sible to completely rule out some protective effect caused
Figure 2. Area under the curve of the plasma release cardiac TnT in patients undergoing coronary artery bypass
grafting with CPB and aortic crossclamping, CPB and cold blood cardioplegia, and on the beating heart without
CPB (*P < .05 vs corresponding control group).
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by this agent. Hypothermia is another cardioprotective fac-
tor26 that may influence the cardioprotection of precondi-
tioning. Recently, Takeshima and colleagues27 also demon-
strated that preconditioning was not protective with deep
hypothermia. However, moderate hypothermia alone, as
used in the present studies, does not inhibit the precondi-
tioning response.
Mechanism of Preconditioning by Cardiopulmonary
Bypass
Although the precise mechanism of IP still remains unclear,
recent investigations have clearly identified a number of
factors that are essential to achieve protection. CPB induces
a systemic inflammatory reaction, and it is possible that
some elements of this reaction may be responsible for the
observed protection. Yamashita and coworkers28 recently
reported that interleukin 1 and tumor necrosis factor  (the
production of which is increased by CPB) cause an eleva-
tion in tissue manganese-superoxide dismutase, which was
demonstrated when brief sublethal ischemia or anoxic in-
sults were induced.29 However, this thesis is unlikely, be-
cause the production of cytokines is a late event in response
to CPB that requires more than 10 minutes.
Recently, our laboratory showed that the generation of
free radical species occurs soon after the institution of
CPB.30 Therefore, it is possible to speculate that free radi-
cals are the primary cause of cardioprotection by CPB. The
relationship between free radicals and preconditioning was
first suggested by Richard and colleagues,31 who showed
that administration of oxygen free radical scavengers during
Figure 3. CK leakage (A) during the 120-minute reoxygenation period and MTT reduction (B) at the end of the
reoxygenation period after 90 minutes of normothermic global ischemia with or without simulated IP. Data are
expressed as mean  SD of 6 experiments (*P < .05 vs corresponding group without preconditioning).
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the first reperfusion period could block the beneficial effect
of preconditioning on infarct size in dogs. They therefore
proposed that the generation of low amounts of free radicals
during the short ischemic episode is not sufficient to cause
cell necrosis but enough to modify cellular activity and
induce preconditioning. More recently, Pain and col-
leagues32 demonstrated that the opening of mitochondrial
KATP channels triggers protection through the generation of
free radicals that activate protein kinase C, an obligatory
step in the signal transduction mechanism of IP. One of the
potential limitations with our in vitro studies is the use of
atrial myocardium as opposed to ventricular myocardium,
and therefore any extrapolation must be conducted with
caution; however, Speechly-Dick and coworkers33 sug-
gested that preconditioning exerts identical protection in
both tissues. Undoubtedly, KATP channels are present in
both atrium and ventricle,34 although their density in both
tissues is unknown.
The induction of CPB affects the body hemodynamics
that may provoke a number of tissue responses. Thus, the
loss of atrial and ventricular filling may stimulate a sympa-
thetic-receptor–mediated release of local catecholamines,
whereas the interruption of pulsatile systolic and diastolic
blood flow to the adrenal glands may stimulate a systemic
catecholamine release. Therefore, an altered adrenergic
state may also be partially responsible for CPB-associated
preconditioning in human myocardium. Several investiga-
tors,35,36 including the current authors,37 have observed that
norepinephrine or phenylephrine triggers preconditioning,
and that this protection is prevented by adrenergic blockade.
Similarly, Thornton and colleagues38 demonstrated that
tyramine, an agent that causes the release of endogenous
catecholamines, reduced infarct size in rabbits when given
before a sustained period of ischemia. Certainly, more stud-
ies are required to elucidate the mechanism of cardiopro-
tection effected by CPB.
Clinical Implications
Cardiac surgical practice is rapidly evolving, and an increas-
ing number of surgeons are adopting surgery on the beating
heart, without the use of CPB, in their practice. Cardioplegic
solutions cannot be used in this situation, and the demon-
stration that interventions such as IP are as effective can
have important clinical implications. However, it should be
recognized that the clinical application of IP may still be
difficult and cumbersome, particularly if minimally invasive
approaches are used. Because of this, the pharmacologic
manipulation of the signal transduction cascade of precon-
ditioning may seem to be a more appropriate alternative. In
this regard, several investigators, including the current au-
thors, are endeavoring to fully elucidate the mechanism of
preconditioning in humans to make this intervention a clin-
ical reality.
CPB is known to induce a systemic inflammatory reac-
tion that is believed to be responsible for increased morbid-
ity. The present studies demonstrate that CPB can also
trigger preconditioning and be cardioprotective.
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